February 17, 2011
Cambridge, MA
Refresh your understanding of Federal Circuit case law in this program designed especially for IP lawyers practicing in biotechnology. Federal Circuit decisions can impact IP portfolio strategy on many levels and in significant or subtle ways. We have selected some decisions of particular importance that are worth a closer look.
Please join Finnegan attorneys Leslie A. McDonell and Amelia Feulner Baur, Ph.D., as they discuss the following biotechnology cases:
- Prometheus Laboratories Inc. v. Mayo Collaborative Services, et al.
- Method of treatment claims and 35 U.S.C. § 101
- Cancer Research Technology Ltd. v. Barr Laboratories, Inc.
- Prosecution latches and inequitable conduct
- Sun Pharmaceuticals Industries, Inc. v. Eli Lilly and Company
- Double patenting
Date:
Thursday, February 17, 2011
Time:
7:30 - 8:00 a.m.
Registration and Breakfast
8:00 - 9:00 a.m.
Program
Where:
Finnegan
55 Cambridge Parkway
Cambridge, MA
Articles
This Article Was Written Entirely by AI — Welcome to Synthetic Patent Litigation
July/August 2026
Federal Circuit IP Blog
July 8, 2026
Federal Circuit IP Blog
July 8, 2026
Articles
When the Classroom Goes Dark: Lessons from the Canvas Breach for Corporate Cyber Preparedness
July 8, 2026
Articles
How Low Can You Go? Courts Lower Marking Defense Burden, Raising Patent Damages Risks
June 29, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.